Vivo Bio Tech Ltd Company Summary

Vivo Bio Tech Limited, established on 12 February 1987 is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies, Genotoxicity screening, Analytical services etc. The Company has pioneered as a primary provider of SPF lab animals in India.

It holds the distinction of being the largest breeder and distributor of rodent models, in addition to offering custom rodent models and stem cell products through Cyagen Biosciences. The Company serves as an authorized distributor of lab animal diets from Special Diets Services (UK) in India. Their comprehensive services span a wide array of preclinical toxicology disciplines, encompassing In-vitro and In-vivo studies, analytical chemistry studies, bioanalytical studies, and physico-chemical studies.

Vivo Bio has partnered with Taconic Biosciences for sourcing foundation and expansion colonies of the animal models and have started in-house breeding of Specific Pathogen Free rodents.The Company partnered Cyagen Biosciences to access genomic technologies in 2016. It commenced breeding and distribution of SPF guinea pigs in 2017. The Company acquired 100% shareholding in M/s.

Donakanti Consulting Services Private Ltd on 17 April, 2019. It received ISO 9001:2015 Certification for Quality Management System. The Company completed NGCMA - OECD GLP Surveillance and Scope Extension with the introduction of inhalational studies in 2019.The Company transformed from an animal breeding and distributing company into a full service CRO with interest in In-vitro, In-vivo, EcoTox, Analytical, Bio -Analytical and Physchem, ADME and PK-PD studies in 2021-22.The canine/large-animal platform became operational in December 2025.

In FY 2026, the Company expanded the toxicology and analytical chemistry infrastructure across multiple specialised domains. It Initiated dog GLP toxicology studies for USA clients. It enhanced bioanalytical capacity with four high-performance LC-MS/MS systems to support small- and large molecule analysis.